Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 404

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 4
Chunk 404
---
 their affiliates.

After the completion of our initial business combination,
members of our management team who remain with us, may be paid consulting, management or other fees from the combined company with any
and all amounts being fully disclosed to shareholders, to the extent then known, in the tender offer materials or proxy solicitation materials
furnished to our shareholders in connection with a proposed business combination. It is unlikely the amount of such compensation will
be known at the time, as it will be up to the directors of the post-combination business to determine executive and director compensation.
Any compensation to be paid to our officers will be determined, or recommenced, to the board of directors for determination, either by
a committee constituted solely by independent directors or by a majority of the independent directors on our board of directors.

We do not intend to take any action to ensure
that members of our management team maintain their positions with us after the consummation of our initial business combination, although
it is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with us after
the initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with
us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability
of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision
to proceed with any potential business combination. We are not party to any agreements with our officers and directors that provide for
benefits upon termination of employment.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS.

The following table sets forth
information regarding the beneficial ownership of our ordinary shares as of the date of this annual report by:

●each person known by us to be the beneficial owner of more than 5% of our issued and outstanding ordinary
shares;

●each of our officers and directors that beneficially owns ordinary shares; and

22

●all our officers and directors as a group.

The following table is based on 33,517,143 ordinary
shares outstanding (inclusive of shares included in outstanding units) outstanding as of the date of this annual report. Unless otherwise
indicated, we believe that all persons named in the table have sole voting and investment power with respect to all ordinary shares beneficially
owned by them. The following table does not reflect record of beneficial ownership of any ordinary shares